Smallpox treatment by RNA Interference

Information

  • Research Project
  • 6643910
  • ApplicationId
    6643910
  • Core Project Number
    R43AI052883
  • Full Project Number
    1R43AI052883-01A1
  • Serial Number
    52883
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/2003 - 21 years ago
  • Project End Date
    2/28/2005 - 19 years ago
  • Program Officer Name
    GREENSTONE, HEATHER LEA
  • Budget Start Date
    9/15/2003 - 21 years ago
  • Budget End Date
    2/28/2005 - 19 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    9/9/2003 - 21 years ago
Organizations

Smallpox treatment by RNA Interference

DESCRIPTION (provided by applicant): While eradicated as an endemic disease, smallpox remains a threat to human health because it may be used by bioterrorists. The potential spread of variola virus or recombinant forms of variola or other poxviruses requires the development of novel therapeutic approaches. We propose to develop and utilize RNA interference (RNAi) technology to treat smallpox. RNAi is accomplished by the introduction of double-stranded RNA into the cell, resulting in sequence specific degradation of the target mRNA. Application of short (21-25 bp) double stranded RNA (siRNA) also induces effective RNAi and limits non-specific effects. We have recently demonstrated that siRNA can be efficiently introduced into mammalian cells in vivo, and can be used to modulate gene expression. In this SBIR Phase I grant proposal, we will determine if poxvirus gene expression can be inhibited by siRNA. For these experiments, we will use vaccinia virus as a highly relevant model for variola virus. Several genes from different viral pathways (transcription, replication, virion formation, virulence) will be targeted in vitro. Effects upon target gene expression and viral replication will be measured. These experiments should demonstrate the feasibility of using siRNA for smallpox therapy or prophylaxis.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    117698
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:117698\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MIRUS BIO CORPORATION
  • Organization Department
  • Organization DUNS
    937904944
  • Organization City
    MADISON
  • Organization State
    WI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    537191264
  • Organization District
    UNITED STATES